Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States.
Revenue (Most Recent Fiscal Year) | $36.85M |
Net Income (Most Recent Fiscal Year) | $-171.67M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 10.57 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 10.50 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -465.80% |
Net Margin (Trailing 12 Months) | -465.80% |
Return on Equity (Trailing 12 Months) | -282.36% |
Return on Assets (Trailing 12 Months) | -62.64% |
Current Ratio (Most Recent Fiscal Quarter) | 3.36 |
Quick Ratio (Most Recent Fiscal Quarter) | 3.36 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.63 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $0.31 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.16 |
Earnings per Share (Most Recent Fiscal Year) | $-1.48 |
Diluted Earnings per Share (Trailing 12 Months) | $-1.50 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 121.30M |
Free Float | 106.14M |
Market Capitalization | $389.38M |
Average Volume (Last 20 Days) | 1.50M |
Beta (Past 60 Months) | 1.50 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 12.50% |
Percentage Held By Institutions (Latest 13F Reports) | 93.92% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |